Treatment in patients with osteoarthritis at different sites: Place of slow-acting drugs
The main goal of osteoarthritis (OA) treatment is to perform rational analgesic and anti-inflammatory therapy, to slow down the progression of the disease, and to preserve quality of life in patients. The performance of analgesic therapy in the elderly is impeded by the presence of a concomitant dis...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2015-06-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/625 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849338588540436480 |
|---|---|
| author | N. V. Chichasova G. R. Imametdinоva |
| author_facet | N. V. Chichasova G. R. Imametdinоva |
| author_sort | N. V. Chichasova |
| collection | DOAJ |
| description | The main goal of osteoarthritis (OA) treatment is to perform rational analgesic and anti-inflammatory therapy, to slow down the progression of the disease, and to preserve quality of life in patients. The performance of analgesic therapy in the elderly is impeded by the presence of a concomitant disease, primarily that of the cardiovascular system and gastrointestinal tract. A group of experts has elaborated the algorithm for managing OA patients, which tracks a careful approach to using nonsteroidal anti-inflammatory drugs and confirms the efficacy of slow-acting agents (chondroitin sulfate (CS) and glucosamine) and intraarticular hyaluronate. The experts have concluded that the use of symptomatic slow-acting drugs for the treatment of OA (SYSADOA), if need be, in combination with short-term paracetanol cycles as basic therapy for this condition is safer and more effective. The 2003 EULAR guidelines identify CS and glucosamine as chondroprotectors. Many studies have shown that CS and glucosamine have a moderate or significant effect on joint pain syndrome and functional mobility in OA; they are safe and characterized by minimal side effects. Long-term qualitative randomized controlled trials have demonstrated that CS and glucosamine are able to slow down the progression of joint space narrowing in OA. It is also shown that the use of a combination of glucosamine and CS allows cartilage loss to be prevented. |
| format | Article |
| id | doaj-art-1d5b5f8eaa274a8caeaff1c8b35266b4 |
| institution | Kabale University |
| issn | 1996-7012 2310-158X |
| language | Russian |
| publishDate | 2015-06-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Современная ревматология |
| spelling | doaj-art-1d5b5f8eaa274a8caeaff1c8b35266b42025-08-20T03:44:21ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2015-06-0192667410.14412/1996-7012-2015-2-66-741920Treatment in patients with osteoarthritis at different sites: Place of slow-acting drugsN. V. Chichasova0G. R. Imametdinоva1I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia 8, Trubetskaya St., Build. 2, Moscow 119048V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia 34A, Kashirskoe Shosse, Moscow 115522The main goal of osteoarthritis (OA) treatment is to perform rational analgesic and anti-inflammatory therapy, to slow down the progression of the disease, and to preserve quality of life in patients. The performance of analgesic therapy in the elderly is impeded by the presence of a concomitant disease, primarily that of the cardiovascular system and gastrointestinal tract. A group of experts has elaborated the algorithm for managing OA patients, which tracks a careful approach to using nonsteroidal anti-inflammatory drugs and confirms the efficacy of slow-acting agents (chondroitin sulfate (CS) and glucosamine) and intraarticular hyaluronate. The experts have concluded that the use of symptomatic slow-acting drugs for the treatment of OA (SYSADOA), if need be, in combination with short-term paracetanol cycles as basic therapy for this condition is safer and more effective. The 2003 EULAR guidelines identify CS and glucosamine as chondroprotectors. Many studies have shown that CS and glucosamine have a moderate or significant effect on joint pain syndrome and functional mobility in OA; they are safe and characterized by minimal side effects. Long-term qualitative randomized controlled trials have demonstrated that CS and glucosamine are able to slow down the progression of joint space narrowing in OA. It is also shown that the use of a combination of glucosamine and CS allows cartilage loss to be prevented.https://mrj.ima-press.net/mrj/article/view/625osteoarthritistreatment algorithmslow-acting drugsglucosaminechondroitin sulfate |
| spellingShingle | N. V. Chichasova G. R. Imametdinоva Treatment in patients with osteoarthritis at different sites: Place of slow-acting drugs Современная ревматология osteoarthritis treatment algorithm slow-acting drugs glucosamine chondroitin sulfate |
| title | Treatment in patients with osteoarthritis at different sites: Place of slow-acting drugs |
| title_full | Treatment in patients with osteoarthritis at different sites: Place of slow-acting drugs |
| title_fullStr | Treatment in patients with osteoarthritis at different sites: Place of slow-acting drugs |
| title_full_unstemmed | Treatment in patients with osteoarthritis at different sites: Place of slow-acting drugs |
| title_short | Treatment in patients with osteoarthritis at different sites: Place of slow-acting drugs |
| title_sort | treatment in patients with osteoarthritis at different sites place of slow acting drugs |
| topic | osteoarthritis treatment algorithm slow-acting drugs glucosamine chondroitin sulfate |
| url | https://mrj.ima-press.net/mrj/article/view/625 |
| work_keys_str_mv | AT nvchichasova treatmentinpatientswithosteoarthritisatdifferentsitesplaceofslowactingdrugs AT grimametdinova treatmentinpatientswithosteoarthritisatdifferentsitesplaceofslowactingdrugs |